短疗程干扰素α治疗转移性肾细胞癌的活性——一项2期研究。
Activity of a short course of interferon alpha for metastatic renal cell carcinoma--a phase-2 study.
作者信息
Abratt R P, Pontin A R, Ball H S
机构信息
Department of Radiotherapy, Groote Schuur Hospital, Observatory South Africa.
出版信息
Cancer Immunol Immunother. 1993 Jul;37(2):140-1. doi: 10.1007/BF01517047.
Abstract
Twelve patients with metastatic renal cell carcinoma were entered into a phase-2 study of an 8-week course of interferon (INF) therapy. INF was given subcutaneously at a dose of 3 mu, three times per week. The patients were WHO performance status 0-2. A complete response was obtained in two patients (17% response rate), which has been maintained at 23 and 45 months. One of these patients presented with cranial and lung metastases and received cranial irradiation and decradron concurrent with INF. The toxicity of INF has been low. The optimal duration of INF therapy warrants further evaluation.
摘要
12例转移性肾细胞癌患者进入了一项为期8周的干扰素（INF）治疗的2期研究。INF以3百万单位的剂量皮下注射，每周3次。患者的世界卫生组织（WHO）体能状态为0 - 2级。2例患者获得完全缓解（缓解率为17%），缓解状态分别维持了23个月和45个月。其中1例患者有颅骨和肺部转移，在接受INF治疗的同时还接受了头颅放疗和地塞米松治疗。INF的毒性较低。INF治疗的最佳持续时间有待进一步评估。
相似文献
1
Activity of a short course of interferon alpha for metastatic renal cell carcinoma--a phase-2 study.短疗程干扰素α治疗转移性肾细胞癌的活性——一项2期研究。
Cancer Immunol Immunother. 1993 Jul;37(2):140-1. doi: 10.1007/BF01517047.
2
Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.高剂量α-2b干扰素与白细胞介素-2大剂量推注隔日交替给药治疗转移性肾细胞癌：一项II期研究
Cancer. 1993 Sep 1;72(5):1733-42. doi: 10.1002/1097-0142(19930901)72:5<1733::aid-cncr2820720537>3.0.co;2-x.
3
4
The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b.用α-2b干扰素治疗的肾癌、黑色素瘤和结直肠癌患者免疫变化的预后意义。
Cancer Immunol Immunother. 1996 Oct;43(2):94-102. doi: 10.1007/s002620050308.
5
Long-term interferon treatment in metastatic renal cell carcinoma.转移性肾细胞癌的长期干扰素治疗。
Eur Urol. 1989;16(5):378-81. doi: 10.1159/000471621.
6
Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: a phase II study.转移性肾癌长期使用α干扰素的可行性：一项II期研究。
Cancer. 2001 Aug 15;92(4):761-7. doi: 10.1002/1097-0142(20010815)92:4<761::aid-cncr1380>3.0.co;2-#.
7
A phase II trial of concomitant interferon-alpha-2b and granulocyte-macrophage colony-stimulating factor in patients with advanced renal cell carcinoma.晚期肾细胞癌患者联用α-2b干扰素和粒细胞巨噬细胞集落刺激因子的II期试验。
J Immunother Emphasis Tumor Immunol. 1995 Jan;17(1):58-61. doi: 10.1097/00002371-199501000-00007.
8
Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.α干扰素与低剂量白细胞介素-2联合免疫疗法治疗日本转移性肾细胞癌患者的临床疗效
Urol Oncol. 2009 Nov-Dec;27(6):598-603. doi: 10.1016/j.urolonc.2008.07.023. Epub 2008 Sep 25.
9
Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.晚期肾细胞癌和黑色素瘤患者每周交替使用白细胞介素-2和干扰素α-2a的临床及免疫调节作用
Br J Cancer. 1991 Feb;63(2):287-92. doi: 10.1038/bjc.1991.67.
10
Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma.
J Clin Oncol. 1990 May;8(5):881-5. doi: 10.1200/JCO.1990.8.5.881.
本文引用的文献
1
Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection.
Cancer. 1987 Feb 1;59(3 Suppl):668-74. doi: 10.1002/1097-0142(19870201)59:3+<668::aid-cncr2820591317>3.0.co;2-j.
2
Phase II study of alpha interferon on renal cell carcinoma. Summary of three collaborative trials.α干扰素治疗肾细胞癌的II期研究。三项合作试验总结。
Cancer. 1986 Sep 15;58(6):1231-5. doi: 10.1002/1097-0142(19860915)58:6<1231::aid-cncr2820580610>3.0.co;2-#.
3
Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration.重组α干扰素治疗肾细胞癌：两种给药途径的随机试验
J Clin Oncol. 1987 Feb;5(2):286-91. doi: 10.1200/JCO.1987.5.2.286.
4
Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma.复发性或转移性肾细胞癌患者生存的预后因素
Cancer Res. 1988 Dec 15;48(24 Pt 1):7310-3.
5
Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma.不明原因的自发消退及α干扰素作为转移性肾癌的治疗方法
Br J Urol. 1989 Feb;63(2):128-31. doi: 10.1111/j.1464-410x.1989.tb05147.x.
6
An assessment of the current use of human interferons in therapy of urological cancers.对目前人类干扰素在泌尿生殖系统癌症治疗中的应用评估。
J Urol. 1989 Nov;142(5):1173-80. doi: 10.1016/s0022-5347(17)39022-5.
7
Interferon therapy in cancer: from imaginon to interferon.癌症中的干扰素疗法：从想象到干扰素。
Cancer Res. 1986 Sep;46(9):4315-29.
8
Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma. Reduced toxicity without reduction of the response rate--a phase II study.重组干扰素α联合泼尼松治疗转移性肾细胞癌。毒性降低但缓解率未降——一项II期研究
Cancer. 1990 Jun 1;65(11):2451-4. doi: 10.1002/1097-0142(19900601)65:11<2451::aid-cncr2820651108>3.0.co;2-3.
9
Cytokines in clinical cancer therapy.临床癌症治疗中的细胞因子
Curr Opin Immunol. 1991 Oct;3(5):699-705. doi: 10.1016/0952-7915(91)90099-m.
Zotero 插件